CenterWatch

Clinical Trial Details

Overview

Research Study Summary

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

Purpose

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

Patient Inclusion Criteria:

  • Able and willing to give written informed consent and comply with requirements of the study protocol.
  • RA patients who never used biologic medications.
  • RA patients who are on Methotrexate or used it in the past.

Patient Exclusion Criteria:

  • Current or previous evidence of serious uncontrolled cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease.

To Learn more

CW ID:166473
Date Last Changed: July 23, 2013

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Facility Type
N/A

Contact

Fay Chen RN, Clinical Research Coordinator
Rutgers, The State University of New Jersey - Robert Wood Johnson Medical School
Clinical Research Center Acute Care Building, 3rd floor 51 French Street
New Brunswick, NJ 08903
Phone: 732-418-8484
Fax: 732-418-8480

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.